Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PGV002
- Development stage
- Phase 1
- Lead developer
- NeoCura
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
PGV002 is a **personalized neoantigen mRNA cancer vaccine** developed by NeoCura for the treatment of solid tumors and other cancers. As an individualized immunotherapy, PGV002 encodes tumor-specific neoantigens identified from a patient’s cancer, delivered via mRNA to stimulate a targeted immune response against cancer cells. Its main therapeutic aim is to activate and enhance anti-tumor immunity through patient-specific immunostimulation, potentially in both monotherapy and combination therapy settings. The vaccine is administered parenterally and is in the clinical development stage, with initial clinical activity planned in adult patients with solid tumors[1][5][8].
- Other names
- PGV002 mRNA vaccinePGV-002 mRNA vaccinePGV 002 mRNA vaccinePersonalized neoantigen tumor vaccine NeoCura
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on PGV002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PGV002.